Zonisamide — $0 on Listed Strengths
Zonisamide is $0 on listed strengths only. Other strengths are not a blanket $0.
Zonisamide Pricing
| Pricing type | Price |
|---|---|
| TheDrugClub | $0 on listed strengths |
| Typical Retail | $103.00 |
$0 on listed strengths: 100mg Capsules (max 90); 25mg Capsules (max 270); 50mg Capsules (max 270)
About Zonisamide
Zonisamide is a prescription medication. Ask your doctor if Zonisamide is right for you.
How to Check Zonisamide Pricing
- Join TheDrugClub for $19.95/month
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available membership pricing
Zonisamide at Participating Pharmacies
- CVS Pharmacy
- Walgreens
- Walmart Pharmacy
- Rite Aid
- Kroger Pharmacy
- Costco Pharmacy
- Albertsons
- Safeway
- Publix Pharmacy
- H-E-B Pharmacy
Pharmacy participation and fulfillment options vary. Present your membership card and confirm current pricing before filling.
Other medications in Neurological
About Zonisamide
Zonisamide is a vital medication for many individuals managing epilepsy, offering a pathway to better seizure control. At TheDrugClub, we understand the importance of affordable access to such critical prescriptions. Our membership program is designed to help you significantly reduce the cost of zonisamide and many other medications, making your health journey more manageable.
The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.
What Zonisamide is approved for (FDA label)
Zonisamide capsules USP are indicated as adjunctive therapy in the treatment of partial seizures in adults with epilepsy.
Source: Read the full FDA label on DailyMed. Label effective date: September 8, 2026.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Adverse reactions for Zonisamide (FDA label)
The most common adverse reactions with zonisamide (an incidence at least 4% greater than placebo) in controlled clinical trials and shown in descending order of frequency were somnolence, anorexia, dizziness, ataxia, agitation/irritability, and difficulty with memory and/or concentration. In controlled clinical trials, 12% of patients receiving zonisamide as adjunctive therapy discontinued due to an adverse reaction compared to 6% receiving placebo. Approximately 21% of the 1,336 patients with epilepsy who received zonisamide in clinical studies discontinued treatment because of an adverse reaction. The most common adverse reactions leading to discontinuation were somnolence, fatigue and/or ataxia (6%), anorexia (3%), difficulty concentrating (2%), difficulty with memory, mental slowing, nausea/vomiting (2%), and weight loss (1%).
Source: FDA prescribing information (DailyMed). Set ID: 994e3ce0-f30b-47b1-aa42-b1ed37fb7c12. SPL document ID: 5afa5342-1bf4-3c4c-e063-6394a90a86ab. Label effective date: September 8, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Contraindications for Zonisamide (FDA label)
Zonisamide capsules are contraindicated in patients who have demonstrated hypersensitivity to sulfonamides or zonisamide.
Source: FDA prescribing information (DailyMed). Set ID: 994e3ce0-f30b-47b1-aa42-b1ed37fb7c12. SPL document ID: 5afa5342-1bf4-3c4c-e063-6394a90a86ab. Label effective date: September 8, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Drug interactions for Zonisamide (FDA label)
Drug Interactions with CNS Depressants: Concomitant administration of zonisamide and alcohol or other CNS depressant drugs has not been evaluated in clinical studies. Because of the potential of zonisamide to cause CNS depression, as well as other cognitive and/or neuropsychiatric adverse events, zonisamide should be used with caution if used in combination with alcohol or other CNS depressants. Other Carbonic Anhydrase Inhibitors: Concomitant use of zonisamide, a carbonic anhydrase inhibitor, with any other carbonic anhydrase inhibitor (e.g., topiramate, acetazolamide or dichlorphenamide), may increase the severity of metabolic acidosis and may also increase the risk of kidney stone formation or the risk of hyperammonemia. Therefore, if zonisamide is given concomitantly with another carbonic anhydrase inhibitor, the patient should be monitored for the appearance or worsening of metabolic acidosis (see CLINICAL PHARMACOLOGY, Interactions of Zonisamide with Other Carbonic Anhydrase Inhibitors subsection and WARNINGS, Metabolic Acidosis subsection and Hyperammonemia and Encephalopathy subsection).
Source: FDA prescribing information (DailyMed). Set ID: 994e3ce0-f30b-47b1-aa42-b1ed37fb7c12. SPL document ID: 5afa5342-1bf4-3c4c-e063-6394a90a86ab. Label effective date: September 8, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.